At the same time, only four markers, ER, PR, Ki-67, and HER2, are recommended for clinical use and classification of tumor subtypes [179], although, as noted above, research laboratories and some clinical diagnostic laboratories already use considerably more biomarkers. Here, PGR is linked to neoplasm.